Status:
COMPLETED
Brain Network Dynamics of Depression During Esketamine Treatment
Lead Sponsor:
University of North Carolina, Chapel Hill
Conditions:
Depressive Disorder, Major
Eligibility:
All Genders
18-99 years
Brief Summary
This is a monocentric, observational clinical trial investigating the effect of Esketamine on brain network activity and a belief updating task in people with depression. We investigate the immediate ...
Detailed Description
The FDA approved the S-enantiomer of Ketamine in a nasal spray formulation (Esketamine, Spravato) in 2019 for treatment resistant depression in conjunction with an oral antidepressant. Albeit showing ...
Eligibility Criteria
Inclusion
- Major Depressive Disorder
- Receiving Esketamine nasal spray treatment for depression
- Ability to understand study procedures and sign an informed consent.
Exclusion
- None
Key Trial Info
Start Date :
July 3 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2024
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06012916
Start Date
July 3 2023
End Date
August 30 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Carolina Center for Neurostimulation
Chapel Hill, North Carolina, United States, 27516